The human genome encodes a variety of poorly understood RNA species that remain challenging to identify using existing genomic tools. We developed chromatin run-on and sequencing (ChRO-seq) to map the location of RNA polymerase for almost any input sample, including samples with degraded RNA that are intractable to RNA sequencing. We used ChRO-seq to map nascent transcription in primary human glioblastoma (GBM) brain tumors. Enhancers identified in primary GBMs resemble open chromatin in the normal human brain. Rare enhancers that are activated in malignant tissue drive regulatory programs similar to the developing nervous system. We identified enhancers that regulate groups of genes that are characteristic of each known GBM subtype and transcription factors that drive them. Finally we discovered a core group of transcription factors that control the expression of genes associated with clinical outcomes. This study characterizes the transcriptional landscape of GBM and introduces ChRO-seq as a method to map regulatory programs that contribute to complex diseases. NaTuRE GENETiCS | VOL 50 | NOVEMBER 2018 | 1553-1564 | www.nature.com/naturegenetics
H uman genomes encode a wealth of functional elements that have critical roles in the molecular basis of disease. RNAs serve as markers for a surprisingly diverse group of functional elements, indicating the expression level of protein-coding genes (messenger RNAs), as well as the location of enhancers and other non-coding regulatory elements that transcribe short and rapidly degraded non-coding RNAs (ncRNAs) [1] [2] [3] [4] [5] . However, the discovery of ncRNA species, particularly of enhancer-templated RNAs that are characteristic of distal regulatory elements 2, 5 , has proved challenging. Most ncRNAs are not represented in RNA-seq data, owing to the rapid degradation rates of most ncRNAs by the nuclear exosome complex 6, 7 . Chromatin immunoprecipitation and sequencing (ChIP-seq) for RNA polymerase II is of limited value because it has a poor signal-to-noise ratio, which obscures less abundant RNA species 8 . Likewise, assays that measure nuclease accessibility, such as DNase-seq 9 (DNase I digestion and sequencing) and ATAC-seq 10 (assay for transposase-accessible chromatin with high-throughput sequencing), are poor sources of information about transcriptional activity because they identify open chromatin regions irrespective of activity, and they do not provide critical information about mRNAs such as gene expression levels or transcript boundaries.
Recent studies have shown that sequencing of nascent RNAs attached to an actively transcribing RNA polymerase complex is an effective strategy for discovering coding and ncRNAs [11] [12] [13] [14] [15] [16] [17] [18] . Nascent RNA-seq techniques, such as precision nuclear run-on sequencing (PRO-seq) 13 , provide markedly higher sensitivity for detecting shortlived ncRNAs than techniques which measure total RNA. Thus, PRO-seq and related assays provide a rich source of information about multiple layers of regulatory control, enabling simultaneous measurements of transcription at protein-coding genes and the discovery of active regulatory elements, including enhancers [19] [20] [21] .
Cancers are a particularly attractive target for nascent RNA sequencing techniques because cancer is a disease of gene regulation 22 . In most cancers, somatic changes to DNA sequence affect oncogenic or tumor suppressive pathways 23, 24 . In some cases, somatic mutations affect the core transcriptional machinery directly 25 , motivating the use of assays that measure the localization of RNA polymerase II (Pol II) directly. Somatic mutations initiate secondary changes in gene expression that are in turn responsible for initiating changes in cell morphology and behavior that are characteristic of malignancy. For this reason, gene expression signatures from RNAseq and other assays have proved effective as biomarkers, denoting cancer subtypes that are associated with progression and survival. However, which genes undergo regulatory changes in cancer, and in particular the identity of key transcription factors that encode the malignant behaviors of cancer cells by their effect on target genes, remain poorly defined. Nascent RNA sequencing techniques remain challenging to apply in some cell lines, and in particular to intact clinical isolates derived from patients with cancer. Here, we introduce a new protocol called chromatin run-on and sequencing (ChRO-seq). ChROseq produces similar maps of transcription to PRO-seq in cell lines, but it can also be applied to solid tissue samples, including those in which RNA is highly degraded. We used ChRO-seq to analyze 24 human glioblastoma (GBM) brain tumors, patient-derived xenografts (PDXs) and a primary non-malignant brain sample, and through this technique we have gained new insights into the molecular etiology of GBM.
Results
Run-on assays in solid tissue. We developed ChRO-seq, a method to map RNA polymerase in cell or tissue samples (Fig. 1a ). The primary challenge of using PRO-seq is often to obtain nuclei that are suitable for a run-on reaction. We therefore developed an alternative method that relies on fractionating insoluble chromatin, including engaged Pol II 26 (see Methods). Insoluble chromatin was re-suspended by sonication and used as the input sample for a run-on reaction (Fig. 1a ). The run-on was designed to incorporate a biotinylated nucleoside 5′ -triphosphate (NTP) substrate into the existing nascent RNA that provides a high-affinity tag used to enrich nascent transcripts. The biotin group prevents the RNA polymerase from elongating after being incorporated into the 3′ end of the nascent RNA when performed in the absence of normal NTPs, thus enabling up to single-nucleotide resolution for the polymerase active site 13, 27 .
We performed matched ChRO-seq and PRO-seq experiments in the human Jurkat T-cell leukemia line, in which both nuclei and chromatin could be obtained. Median ChRO-seq signal across annotated genes was within the range of variation observed in PROseq data from the same cell line ( Supplementary Fig. 1 ). In contrast, we noted differences in the pause peak and in transcription levels beyond the polyadenylation site compared with data from mammalian native elongating transcript sequencing (mNET-seq) and genome-wide sequencing of nascent RNA (Nascent-seq), two other chromatin-based RNA sequencing assays 14, 28, 29 (Supplementary Note 1). ChRO-seq and PRO-seq produced highly correlated levels of RNA polymerase in the bodies of mRNA encoding genes (R = 0.98; Fig. 1b ). Likewise, signal for paused Pol II was highly correlated across the 5′ ends of annotated genes (R = 0.96; Fig. 1c ), and pause levels in our test ChRO-seq library were within the range of variation observed using nuclei ( Supplementary Fig. 2 ). The microRNA miR-181 locus illustrates the advantages of ChRO-seq compared with other molecular assays (Fig. 1d ). Notably, both ChRO-seq and PRO-seq discovered the primary transcript encoding MIR181 as well as dozens of enhancer-templated RNAs that were not discovered using RNA-seq.
Because RNA prepared from archival tissues is often highly degraded, such samples are poor candidates for genome-wide transcriptome analysis using RNA-seq. The RNA polymerase-DNA complex is more stable than RNA 30 , suggesting that engaged polymerases may provide an avenue for producing new RNAs in archived samples. We obtained a primary GBM (grade IV, ID number GBM-88-04) that was stored in a tissue bank for 30 years. Analysis confirmed that RNA was highly degraded in this sample (RNA integrity number (RIN) = 1.0, Supplementary Fig. 3 ), thus precluding the application of RNA-seq (which requires an RIN of 2-4). To measure gene expression in this sample, we devised length-extension ChRO-seq (leChRO-seq), a variant of ChRO-seq that uses transcriptionally engaged Pol II and a mix of biotinylated NTP and normal NTPs to extend degraded nascent RNA transcripts ( Fig. 1a ). Libraries prepared without an extended run-on had a median insert size of 20 bp, precisely the length of RNA protected from degradation by the polymerase exit channel 31 , whereas run-on samples achieved a longer RNA length distribution that was better suited for mapping unique reads within the human genome ( Fig. 1e ). Although RNA degradation could, in principle, destabilize RNA polymerase, we nevertheless observed that leChRO-seq produced maps of transcription that correlated with those obtained using ChRO-seq and PRO-seq, suggesting that leChRO-seq accurately measures gene expression and Pol II pausing ( Supplementary Figs. 1a, 2, 4 ). Thus, leChRO-seq enables the robust interrogation of archival tissue samples that cannot be analyzed using standard genomic tools.
Maps of transcription in primary GBMs. To demonstrate how
ChRO-seq can provide insights into complex disease, we obtained ChRO-seq or leChRO-seq data from 20 primary GBMs, three PDXs, and a non-malignant brain ( Fig. 2a and Supplementary Table 1 ). Histopathology showed hallmarks of grade IV malignant astrocytoma in all GBMs (for example, GBM-15-90, Supplementary Fig. 5 ). We sequenced ChRO-seq data from each GBM to an average depth of 33 million uniquely mapped reads per sample (10-150 million reads per sample). We confirmed that data collected from biopsies isolated from nearby regions (technical replicates) were highly correlated ( Supplementary Fig. 4c -f and Supplementary Note 2). To gain further insight into how transcription changes in malignant tissue, we analyzed transcription within annotated proteincoding genes and ncRNAs. GBMs from our cohort represent each of the four previously reported molecular subtypes 32 ( Fig. 2b and Supplementary Fig. 6 ). Although most tumors have transcription patterns characteristic of one dominant molecular subtype, several tumors in our cohort were similar to multiple subtypes, particularly those matching neural and mesenchymal signatures, consistent with reports of cellular heterogeneity within the same tumor [33] [34] [35] (Fig. 2b ). We identified 2,381 protein-coding genes and 1,123 ncRNAs that were differentially transcribed across all 20 primary GBMs relative to replicates of the non-malignant brain (P < 0.05, false discovery rate (FDR)-corrected Wald test, DESeq2 36 ) (Supplementary Table 2 ). Differentially transcribed genes had notable enrichments in biological processes related to cell cycle, DNA replication and metabolic processes, development (upregulated in the tumor) and nervous system homeostasis (downregulated) ( Supplementary Fig. 7 ). For example, multiple transcription factors with a role in specifying nervous system development were expressed more highly in nearly all tumors, including the HOX gene clusters and engrailed 1 and 2 (EN1 and EN2) ( Fig. 2c and Supplementary Fig. 8 ). Notably, we identified several differentially transcribed long non-coding RNAs (lncRNAs) that confer growth advantages to U87 GBM cells [37] [38] [39] [40] (for example, AC016831.7, PVT1 and SNHG1) ( Fig. 2c and Supplementary Table 3 ). Taken together, our analysis of ChRO-seq data identified transcriptional changes in both genes and lincRNAs that were shared between GBMs in our cohort.
GBM enhancers retain signatures of normal brain tissue. Active transcriptional regulatory elements (TREs), including promoters and enhancers, have a characteristic pattern of RNA polymerase initiation that enables their discovery using ChRO-seq data 2, 5, 17, [19] [20] [21] . We developed a novel algorithm to identify the precise location of active TREs, called dREG-HD (discriminative regulatory-element detection from GRO-seq, high-definition), which takes GRO-seq, PRO-seq or ChRO-seq data as the input and identifies TREs that are similar to the subset of DNase I hypersensitive sites (DHSs) that exhibit local transcription initiation. The dREG-HD algorithm improved the resolution of dREG 19 by imputing smoothed DNase-seq signal intensity, and identified sites initiating transcriptional activity with 80% sensitivity at > 90% specificity ( Supplementary Fig. 9 ). dREG-HD recovered the nucleosome-depleted region in ChIP-seq and MNase-seq data ( Supplementary Fig. 10 ), which demonstrates that it has substantially higher resolution than dREG alone.
The vast majority (96%) of TREs identified by dREG-HD in each sample of primary GBM were DHSs in at least 1 of the 216 reference tissues analyzed by ENCODE or Epigenome Roadmap 41, 42 . However, most DHSs were discovered in only a few of the tissues in the reference dataset ( Fig. 3a ) and were distal (> 1 kb) to annotated transcription start sites ( Fig. 3b ), suggesting that many reflect the activity of cell-type-specific distal enhancers in the tumor. Rare distal TREs (herein referred to as 'enhancers') provide a unique 'fingerprint' for quantitatively evaluating the similarity between two samples, and could be used to define the relationship between tumors and normal tissue.
We developed a strategy that compares active enhancer landscapes obtained using dREG-HD with DHSs across all public datasets (see Methods). Our strategy discovered the expected cell lines consistently ( Supplementary Fig. 11 ), and furthermore it identified the expected genotype (GM12878) among all lymphoblastoid cell lines as the most similar to GM12878 GRO-seq data ( Supplementary Fig. 11a ). Using unique enhancers to 'fingerprint' primary GBM samples revealed enhancer landscapes that were highly similar to normal brain reference samples compared with other reference tissues ( Fig. 3c and Supplementary Fig. 12 ). In GBM-15-90, for example, 86% of TREs were shared with primary brain tissue, and this was a greater similarity than observed with GBM cell lines (62% TRE identity) or in vitro cultured primary brain cells (75%) ( Supplementary Fig. 13 ). Clustering of TREs in several brain-related cell types suggested that differences between primary tumors and GBM cell lines were caused by differences in the tumor microenvironment ( Fig. 3d , Supplementary Fig. 14 
and Supplementary Note 3).
To evaluate whether contamination of the GBM with normal brain tissue explained the extensive similarity with normal brain reference samples, we used leChRO-seq data from three PDXs, in which primary GBMs were grown in a murine host. In PDXs, murine cells replace both normal tissue and stroma 43 , and can be distinguished from tumor cells based on species-specific differences in DNA sequence. Mutual information ranked all PDX samples as similar to the normal human brain compared with all other samples ( Fig. 3c ). Thus, we conclude that primary GBM cells are more similar to their cell of origin than may have been anticipated based on the analysis of cell models.
TREs define three distinct regulatory programs activated in GBM tissue. TREs that were active in tumor tissue, but were not DHSs in any of the available adult brain reference samples, may contribute to the malignant phenotype of the tumor. Such tumor-associated TREs (taTREs) comprised 2-24% of TREs in each tumor ( Supplementary  Figs. 15 and 16 and Supplementary Table 4 ). We developed a statistical test to identify tissues that shared unexpectedly high overlap with taTREs identified in each tumor that controls for DHS scarcity (Supplementary Table 4 ) (see Methods). Hierarchical clustering of the taTREs among enriched cell or tissue types identified three regulatory programs that were enriched in the primary GBMs; one resembling a stem-like regulatory program, one associated with differentiated support cells, and a cluster of immune cells ( Fig. 4a and Supplementary Fig. 17 ). taTREs frequently overlapped DHSs (P < 0.0001 bootstrap test) in fetal tissues of the nervous system (a 2.3-6.6-fold enrichment in 11 out of 23 GBMs), in particular of the spinal cord and brain, which were derived from the neuroectoderm ( Fig. 4a , see 'Outlier tissue'). We also found evidence of enrichment in other developmental tissues; for example, embryonic stem cells and other fetal tissues from a variety of germ layers, and for a number of terminally differentiated support cell lineages, including astrocytes, endothelial cells, fibroblasts and osteoblasts. Regulatory programs were partially correlated with previously defined molecular subtypes in GBM ( Fig. 4b and Supplementary Note 4). We emphasize that activation of these separate transcriptional regulatory programs may reflect gene expression changes in subsets of cells within the tumor. Overlap between taTREs and fetal brain tissue is likely to reflect the activation of a regulatory program that promotes stem-like properties that are observed in a population of GBM cells 44 . Similarly, overlap with astrocytes, endothelial cells, fibroblasts or osteoblasts may capture tumor cells that have transdifferentiated into these lineages 45, 46 . Notably, these two signatures were detected in PDX samples as well as primary GBMs, demonstrating that these signatures reflect transcriptional diversity in malignant cells.
To identify transcription factors that may be involved in maintaining each regulatory program, we classified the taTREs in each tumor sample into regulatory programs based on the cell or tissue types in which they overlap a DHS, and searched for enriched transcription factor binding motifs (P < 2.66 × 10 -5 = [0.05/1,882] in at least one patient, Fisher's exact test, rtfbsdb, v.0.4.0 47 ). As we were limited in our ability to distinguish between paralogous transcription factors that share similar DNA binding specificities, we clustered motifs into 14 distinct groups, each associated with multiple transcription factors that may contribute to differences in expression ( Fig. 4c ). Many of these motifs showed mutually exclusive enrichment in the three regulatory programs ( Fig. 4c and Supplementary Fig. 18 ), supporting the hypothesis that each regulatory program is a transcriptionally distinct program mediated by a different group of transcription factors. We identified POU-domain-containing transcription factors enriched in taTREs in the stem-like regulatory program. As predicted, taTREs in the stem-like program were enriched in both ChIP-seq reads and peak calls for POU3F2 in cultured glioma neurospheres 44 ( Supplementary Figs. 19 and 20) . The differentiated support cell program was highly enriched for motifs recognized by activating protein 1 (AP1), a heterodimer of the transcription factors FOS and JUN, a motif resembling heat shock factor 1 (HSF1), and the TEA domain transcription factors (TEAD) family (Fig. 4c ). The immune program was enriched for motifs recognized by the CCAAT/enhancer-binding protein (C/EBP) family, nuclear factor-κ B (NF-κ B) family and the retinoic acid receptor family (RAR), in agreement with reports that at least two of these factors have an important role in inflammatory responses in GBM 48, 49 . Taken together, we have identified taTREs that correlate with complex behaviors intrinsic to malignant cellsfor instance the stem-like regulatory program that was shared with neuroectodermal tissue-and identified candidate transcription factors that may contribute to each behavior.
Transcription factors that control GBM subtype. Transcriptional heterogeneity among GBMs is established primarily by the differential activity of transcription factors. To identify transcription factors that are involved, we focused on TREs with evidence of expression changes among the four previously described molecular subtypes (P < 0.01, FDR-corrected Wald test, DESeq2) (Supplementary Table 5 ). We identified 38 binding motif clusters with extremely strong evidence of enrichment in active TREs with biased transcription in any subtype (P < 2.66 × 10 -5 = [0.05/1,882], Fisher's exact test, Fig. 5a ). Enriched motifs passing our stringent multiple testing correction threshold were most common in the mesenchymal and neural subtypes, and several of these motifs, including those recognized by NF-κ B and C/EBP family, are supported by existing literature 48, 49 . In addition, we identified a number of novel motifs that correlate with subtype-biased expression, including RAR, SRF, SOX family and FOX family members.
Next, we set out to identify target genes that are regulated by each transcription factor in GBM cells. We assumed that molecular subtypes described in the current literature do not completely describe the full range of heterogeneity among GBMs. To identify motifs that contribute to heterogeneity and that are only weakly correlated with the known molecular subtypes, we relaxed our statistical cutoff to a more permissive threshold at which we expected substantially higher sensitivity at an acceptable false discovery rate (P < 0.05, nominal Fisher's exact test, Supplementary Fig. 21 , see Methods). We identified bound occurrences of each enriched motif using heuristics that provide substantial performance improvements over existing high-resolution tools 50, 51 . Motif occurrences were connected with the closest two annotated genes sharing similar subtype bias within 50 kb ( Fig. 5b, Supplementary Figs. 22,23 ), using fairly stringent heuristics to limit false discovery rates (see Methods). We validated target genes by confirming that genes sharing a common transcription factor were more highly correlated across 174 primary GBMs 24 than expected based on randomly selected genes sharing the same subtype specificity ( Fig. 5c , Supplementary Fig. 24a and Supplementary Note 5). We also confirmed that predicted target genes of STAT1 and NF-κ B were enriched for changes after activating those specific transcription factors (Supplementary Note 5) 52, 53 . Thus, we have identified transcription factors that contribute to major GBM expression subtypes and their putative target genes.
Direct inference of transcription factor regulatory activities in GBMs. The gene-regulatory trans activities that a transcription factor has on its complement of bound TREs can be regulated by multiple transcriptional and post-transcriptional mechanisms. Although in some cases a transcription factor is controlled predominantly by the abundance of its protein, many require a subsequent step such as post-transcriptional activation of the protein product to regulate target genes ( Fig. 6a ). We asked whether we could distinguish between these two broad regulatory activities by using ChRO-seq, and using an integrative analysis incorporating both ChRO-seq and publicly available mRNA sequencing (mRNA-seq) data.
In the simplest mode of regulation, the gene-regulatory activity of a transcription factor is determined by the abundance of its protein, which can be correlated with the transcriptional activity of its gene and the abundance of its mRNA. To detect this type of regulatory activity, we asked whether motifs enriched in active TREs of each subtype correspond to changes in Pol II density on the primary transcription unit encoding any one of the transcription factors that recognize the corresponding binding motif. In some cases, we observed transcriptional changes in the transcription factor coding gene in the same subtype in which we also observed motif enrichment (Fig. 6b,c and Supplementary Fig. 24b,c) . For example, ChROseq signal in the gene body encoding the transcriptional activator CEBPB (CCAAT/enhancer-binding protein B) increased by 4.88fold in mesenchymal tumors (Fig. 6b ), consistent with a 2.43-fold enrichment of its corresponding motif in mesenchymal upregulated TREs (Fig. 5a ). Likewise, we found several cases in which mRNA encoding each transcription factor was correlated with the expression of its putative target genes across GBMs to a greater extent than expected based on a null model that controls for molecular subtype (Fig. 6c ; see Methods).
We devised a strategy to estimate which transcription factors have gene-regulatory activities that are regulated by transcriptional or post-translational mechanisms. Focusing on the 25 unique motifs enriched in upregulated TREs that are associated with multiple transcription factors, we found evidence of correlated changes for 8 motifs in ChRO-seq data and for 16 in mRNA-seq data (Fig. 6b,c) . Several of these correlations were weak in magnitude, which may be consistent with gene-regulatory activities controlled by multiple regulatory mechanisms for these transcription factors. We conservatively identified at least six transcription factors, including TEAD, GATA, HSF and NF-κ B, that had low correlations with their putative targets in RNA-seq and no evidence of transcriptional changes in ChRO-seq. These transcription factors seem to be regulated primarily at a post-transcriptional level in GBM.
Transcription factors control groups of survival-associated genes in mesenchymal GBMs. Known molecular subtypes of GBM do not correlate with survival 32 , presenting a motivation to identify new classifiers that may have prognostic value. We reasoned that the activity of transcription factors that control transcriptional heterogeneity among patients with GBM may control biological functions associated with survival. To determine whether gene-regulatory activities of transcription factors may be useful in predicting clinical outcomes, we compared the hazard ratios at putative target genes of each subtype-biased binding motif. We analyzed two sets of nontarget control genes: the nearest annotated transcription start site (within 50 kb) of each subtype-biased TRE that was not changed in that subtype; and differentially transcribed genes in the same subtype that were not identified as targets, because the transcription start site was more than 0.5 Mb away from the nearest putative binding site (see Methods). Our analysis identified six transcription factors significantly associated with poor clinical outcomes, all in mesenchymal tumors (P < 1.16 × 10 -4 = [0.05 / 432], Wilcoxon, Fig. 7a and Supplementary Fig. 25 ). We clustered motifs into three unique DNA binding specificities recognized by RAR, C/EBP and NF-κ B family transcription factors ( Supplementary Fig. 26 ). Only one of these transcription factors, C/EBP, was encoded by a gene (CEBPB) that was associated with survival at the mRNA level ( Supplementary Fig. 27 ), consistent with the correlation of the generegulatory activity of C/EBP with the abundance of its mRNA (Fig. 6b ). NF-κ B activity was correlated to radioresistance in GBMs, and in Supplementary Table 4 ). The Spearman's rank correlation heatmap (left) shows the correlation in motif recognition. Families of transcription factors and their representative motifs are highlighted. b, Schematic illustrating the heuristics used to identify target genes of subtype-biased transcription factors and for defining non-target (control) genes. Changes in transcription of both target and non-target genes are of the same direction as that of subtype-biased TREs. Target genes are the first and second genes within 50 kb of the TRE. Non-target genes are at least 0.5 Mb away. c, Barplots showing the -log 10 Wilcoxon rank-sum P value for higher correlations among target genes of each transcription factor binding motif than a control set (columns; n = 174 TCGA patients with RNA-seq data available). Barplots are colored by the subtype in which they were found to be enriched (P < 0.05, two-sided Fisher's exact test). The Spearman's rank correlation between the binding sites of each motif is shown (bottom). Transcription factor families are indicated below the plot. The dotted line shows the Bonferroni-adjusted threshold for the between-target validation experiment. AP-1, activating protein 1. this case its activity was shown to be regulated post-transcriptionally by monitoring the phosphorylated state of the RELA subunit 48 . This provides further support for the association of a second of the transcription factors identified here with clinical outcomes. In addition, we identified RAR, which to our knowledge has not been linked to survival in GBM.
Surprisingly, all three survival-associated transcription factors regulated overlapping sets of putative target genes. Of four different combinations in which multiple transcription factors could regulate overlapping targets, three were more common than expected (P < 0.01, super exact test 53 , Fig. 7b and Supplementary Fig. 28) , including 44 target genes that were shared among all three transcription factors. Such genes had significantly higher hazard ratios than unique target genes ( Fig. 7c , P = 0.0011, Wilcoxon). Of the 26 shared targets for which hazard ratios were available, all were negatively correlated with survival, and eight were significantly associated with clinical outcomes on their own (a significant enrichment; P = 0.0006, Fisher's exact test), including CCL20 ( Supplementary Fig. 29a ) and ADM (Fig. 7d ), (P < 0.05, chi-squared test) (Supplementary Table 6 ). High expression of both genes was associated with high risk regardless of subtype assignment, indicating that survival association of these transcription factors was not simply driven by enrichment in the mesenchymal subtype ( Supplementary Fig. 29b,c) . Together these 26 genes formed a prognostic signature that strongly predicted overall survival (Fig. 7e ). Moreover, differences in survival among these genes were not driven by IDH1 (encoding isocitrate dehydrogenase 1) status ( Supplementary Fig. 30 ). Gene ontology analysis found that targets of all three transcription factors were enriched for immune system process and stress responses (P < 0.000001, FDR-corrected Fisher's exact test, Supplementary Table 7 ). Taken together, our analysis suggests that C/EBP, RAR, and NF-к B work in concert to activate a shared regulatory program that controls inflammatory processes and correlates with poor clinical outcomes in GBM.
Discussion
Nascent transcription is a promising approach for studying the molecular basis of complex disease because unstable RNAs provide deep insights into multiple stages of gene regulation. ChRO-seq can map nascent transcription in many samples that maintain the integrity of protein-DNA interactions, even those in which RNA is highly degraded. ChRO-seq has the potential to be used across the biomedical sciences to analyze regulatory programs that contribute to solid tumors and other tissues that have proved challenging to study using existing molecular tools. Our analysis of 20 primary tumors provide several insights into transcriptional regulatory programs in malignant tissue. First, we report that enhancers in malignant tissue are surprisingly similar to DHSs in the tissue of origin. This finding suggests that regulatory programs in GBM seem to work within the confines of chromatin architecture that is established in the initiating cell. Regulatory programs are also similar to normal brain in PDXs, demonstrating that tumor-initiating cells are able to reconstitute a diverse cell environment that bares surprising similarity to primary brain tissue. Yet malignant cell behaviors are specified by cancer cells despite this similarity. This may be explained by our discovery of a rare population of ectopic enhancers that resembled fetal tissues isolated from the nervous system, immune cells, and differentiated tumor cells. rank-sum test P value comparing the distribution of hazards ratios of target genes for each transcription factor and two groups of non-target control genes (see Methods). The radius of the circle denotes the -log 10 P value of association between transcription factor messenger RNA levels and survival. Color denotes the log e of the hazard ratio at higher mRNA levels. The dotted red line represents the Bonferroni-adjusted α threshold (0.05/432). b, Venn diagram showing overlap between the target genes of the three indicated transcription factors. c, Violin plot shows the log e hazard ratios for target genes shared among (left, n = 26) and unique to (center, n = 62) three transcription factors, and for mesenchymal marker genes (right, n = 161). Mean hazard ratios are shown by white dots and standard deviations are shown by bars. P values were calculated using a two-sided Wilcoxon rank-sum test. d, Browser track of ADM shows the average of reads per million-normalized leChRO-seq signals and dREG-HD scores in mesenchymal (MES, n = 3) and non-MES (n = 8) GBMs. MES-biased TREs and motif positions are highlighted in blue. e, Kaplan-Meier plot showing overall survival for 196 patients with high and low average expression levels of 26 shared target genes. The cutoff was determined based on the minimum P value in the difference between survival time using a two-sided chisquared test. Shaded regions mark the 95% confidence interval.
Our observations are consistent with models of tumorigenesis in which tumor cells reactivate regulatory programs that are similar in some respects to earlier developmental stages 54 . These regulatory signatures derived from rare ectopic enhancers may have important prognostic value that can be exploited in future studies.
Our study highlights how transcription factors can be responsible for coordinated changes in the expression of groups of genes that contribute to expression heterogeneity among tumors. ChRO-seq, like other run-on technologies 55 , provides substantial information about the regulatory activities of transcription factors on chromatin that is independent of transcription factor mRNA expression levels. In support of our general approach, transcription factor candidates activating TREs in the stem-like regulatory program were similar to those reported previously to be sufficient for initiating tumors in a murine host 44 . In addition, we used ChRO-seq data to identify transcription factors correlated with gene expression patterns in each GBM subtype.
We report three transcription factors, C/EBP, RAR and NF-к B, whose target genes are systematically correlated with poor clinical outcomes. Our work adds new transcription factors to the current literature, as well as additional support for the role of C/EBP in driving mesenchymal transformation 49 . NF-к B was previously associated with resistance to radiotherapy and involvement in mesenchymal transformation in GBMs 48 . Our present work builds on these studies, indicating that NF-к B activation has an unambiguous influence on clinical outcomes. In addition, we found evidence that a third transcription factor, RAR, drives regulatory programs that contribute to survival in GBMs. Notably, post-transcriptional mechanisms seem responsible for activating two of these three transcription factors; NF-к B and RAR. Thus, insights reported here were possible only because ChRO-seq is a more direct indicator of transcription factor activity than other tools applied previously in GBM. As the pharmacology for targeting diverse transcription factor families develops, the transcription factors reported here, as well as our strategies for finding them, should become more useful in nominating targeted therapies.
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Methods
Cell culture. Jurkat cells were grown in RPMI-1640 medium supplemented with 10% fetal bovine serum, 1× penicillin streptomycin antibiotic, 0.125 mg ml -1 gentamicin antibiotic at 37 °C, 5% CO 2 . 1 × 10 6 cells were centrifuged at 700g for 5 min at 4 °C. The medium was removed and the cells were rinsed with 1× PBS, and centrifuged again before PBS was removed.
Tissue collection and preparation. GBM-derived cells were prepared from freshly biopsied human tumors obtained with patient consent. The sample collection was approved by the Institutional Review Board of SUNY Upstate Hospital, Syracuse, NY, USA, and followed all relevant ethical regulations. The non-tumor brain sample was dissected from the brain of a patient with epilepsy, also with informed consent and institutional review board approval. To establish patient-derived xenografts, small pieces of freshly resected gliomas were implanted subcutaneously in the flank of athymic nude (nu/nu) mice (Envigo) and serially passaged (mouseto-mouse) 3 times for PDX-UMU88-02, 7 times for PDX-UMU89-08 and 57 times for PDX-88-04 p57, as described previously 56, 57 . All work with mice was approved by the SUNY Upstate Institutional Animal Care and Use Committee and followed all relevant ethical regulations. To prepare chromatin pellets, tissue samples were pulverized in a cell crusher (Cellcrusher). The cell crusher was chilled in liquid nitrogen, and frozen GBM tissue (approximately 100 mg) was then placed in the Cellcrusher, followed by the pestle. The pestle was struck with the mallet until the tissue was fractured into a fine powder.
Chromatin isolation. The chromatin isolation was based on work first described in ref. 26 . For chromatin isolation from cultured cells or tissue, we added 1 ml of 1× NUN buffer (0.3 M NaCl, 1 M Urea, 1% NP-40, 20 mM HEPES, pH 7.5, 7.5 mM MgCl 2 , 0.2 mM EDTA, 1 mM DTT, 20 units per ml SUPERase In Rnase Inhibitor(Life Technologies, AM2694), 1× Protease Inhibitor Cocktail (Roche, 11 873 580 001)). Samples were vigorously vortexed for 1 min. An additional 500 µ l of NUN buffer was added to each sample and vigorously vortexed for an additional 30 s. For length-extension chromatin isolation from cultured cells or tissue, we added 1 ml of 1× NUN buffer, as described previously, with 50 units per ml Rnase Cocktail Enzyme Mix (Ambion, 2286) in place of the Rnase inhibitor. The samples were incubated on ice for 30 min with a brief vortex every 10 min. Samples were centrifuged at 12,500g for 30 min at 4 °C, after which the NUN buffer was removed from the chromatin pellet. The chromatin pellet was washed with 1 ml 50 mM Tris-HCl, pH 7.5, supplemented with 40 units per ml Rnase inhibitor, centrifuged at 10,000g for 5 min at 4 °C, and the buffer discarded. The chromatin was washed two additional times. After washing, 100 µ l of chromatin storage buffer (50 mM Tris-HCl, pH 8.0, 25% glycerol, 5 mM Mg(CH 3 COO) 2 , 0.1 mM EDTA, 5 mM DTT, 40 units per ml Rnase inhibitor) was added to each sample. The samples were loaded into a Bioruptor and sonicated with the power setting on high, with a cycle time of 10 min with cycle durations of 30 s on and 30 s off. The sonication was repeated up to three times as needed to get the chromatin pellet into suspension. Samples were stored at − 80 °C.
ChRO-seq library preparation. After chromatin isolation, the ChRO-seq library preparation closely followed the methods described previously 27 . Chromatin from 1 × 10 6 Jurkat T cells, or 10-100 mg of primary GBM or 100 mg of PDX in 100 µ l chromatin storage buffer was mixed with 100 µ l of 2× chromatin run-on buffer (10 mM Tris-HCl, pH 8.0, 5 mM MgCl 2 ,1 mM DTT, 300 mM KCl, 400 μ M ATP (New England Biolabs (NEB), N0450S), 40 μ M Biotin-11-CTP (Perkin Elmer, NEL542001EA), 400 μ M GTP (NEB, N0450S), 40 μ M Biotin-11-UTP (Perkin Elmer, NEL543001EA), 0.8 units per μ l Rnase inhibitor, 1% Sarkosyl (Fisher Scientific, AC612075000)). The run-on reaction was incubated at 37 °C for 5 min. The reaction was stopped by adding Trizol LS (Life Technologies, 10296-010) and pelleted with GlycoBlue (Ambion, AM9515) to visualize the RNA pellet. The RNA pellet was resuspended in diethylpyrocarbonate (DEPC)-treated water and heat denatured at 65 o C for 40 s. In ChRO-seq, we digested RNA by base hydrolysis in 0.2N NaOH on ice for 8 min, which ideally yields RNA lengths ranging from 40 to 100 bases. This step was excluded from leChRO-seq. Nascent RNA was purified by binding streptavidin beads (NEB, S1421S) and washed as described 27 . RNA was removed from beads by Trizol (Life Technologies, 15596-026) and followed by 3′ adapter ligation using T4 RNA Ligase 1 (NEB, M0204L). A second bead binding was performed followed by a 5′ decapping with RNA 5′ pyrophosphohydrolase (RppH, NEB, M0356S). The 5′ end was phosphorylated using T4 polynucleotide kinase (NEB, M0201L) then purified with Trizol. A 5′ adapter was then ligated onto the RNA transcript. A third bead binding was then followed by a reverse transcription reaction using Superscript III Reverse Transcriptase (Life Technologies, 18080-044) to generate cDNA. cDNA was then amplified using Q5 High-Fidelity DNA Polymerase (NEB, M0491L) to generate the ChRO-seq libraries following the protocol provided by NEB. Libraries were sequenced using the NextSeq500 high-throughput sequencing system (Illumina) at the Cornell University Biotechnology Resource Center.
Mapping ChRO-seq and leChRO-seq sequencing reads. We used our publicly available pipeline (see URLs) to align ChRO-seq and leChRO-seq data. Some libraries were prepared using adapters that contained a molecule-specific unique identifier (first 6 bp sequenced; denoted in Supplementary Table 1) , and for these we removed PCR duplicates using PRINSEQ lite 58 . Adapters were trimmed from the 3′ end of remaining reads using cutadapt 59 with a 10% error rate. Reads were mapped with the Burrows-Wheeler Aligner (BWA) 60 to the human reference genome (hg19) plus a single copy of the Pol I ribosomal RNA transcription unit (GenBank ID U13369.1). The location of the RNA polymerase active site was represented by a single base that denotes the 3′ end (ChRO-seq) or 5′ end (leChRO-seq) of the nascent RNA, which corresponds to the position on the 5′ or 3′ end of each sequenced read, respectively. Mapped reads were converted to igwig format using BedTools 61 and the bedGraphToBigWig program in the Kent Source software package 62 . Downstream data analysis was performed using the bigwig software package (v.0.2-9; see URLs). All data processing and visualization was carried out in the R statistical environment [63] [64] [65] .
Gene transcription analyses. Gene transcription activity quantification for ChROseq and leChRO-seq. We quantified transcriptional activity using gene annotations from GENCODE v25 lift 37, except for the cross-comparison with The Cancer Genome Atlas (TCGA) RNA-seq data, for which we used GENCODE v22 lift 37 to match the annotation of TCGA data. We counted reads in the interval between 500 bp downstream of the annotated transcription start site and the end of the gene for comparisons. This window was selected to avoid counting reads in the pause peak near the transcription start site. We limited analyses to gene annotations longer than 1,000 bp in length.
Molecular subtype classification. Transcriptional activity of characteristic genes for each GBM subtype (n = 23) was quantified by the methods described above. Read counts from each sample were normalized by reads per million total reads, followed by log 2 transformation of pseudocount-adjusted data (reads per million-normalized reads + 1). The transformed read counts were centered to a mean of zero for each gene. The similarity between each sample was measured by Spearman's rank correlation, and clustered using single-link clustering. The similarity of each sample to molecular subtypes 32 was calculated using Pearson's correlation with the centroid of the corresponding subtype.
Differential expression analysis for annotated genes. Patients with gene expression
patterns matching each of the four reported molecular subtypes were treated as biological replicates ( Fig. 2b and Supplementary Table 3 ). Two technical replicates of non-malignant brain were used as control. Differential expression analysis was conducted using DESeq2 (v.1.20.0) and differentially expressed genes were defined as those with a FDR of less than 0.05.
Comparison of TREs with DNase I hypersensitive sites. dREG-HD. dREG-HD was run using the default settings. A complete description of dREG-HD can be found in Supplementary Note 6.
Data processing for calling Dnase I hypersensitive sites and dREG-HD sites. We reprocessed all Dnase-seq data and identified DHSs using a uniform pipeline. We retrieved mapped reads from either ENCODE or Epigenome roadmap projects aligned to hg19. We called peaks in individual biological replicates, 921 samples in total, using MACS2 66 and Hotspot. To group DHSs for each cell and tissue type with high confidence, we took the union of peaks (using the bedtools 'merge' function) from biological replicates followed by intersecting peaks called by Hotspot and MACS2. Lastly, as peaks resulting from intersection might be too narrow and hence might be missed during downstream intersection operations, we expanded all short peaks (< 150 bp) to 150 bp from the peak center. Analyses involving individual replicates ( Supplementary Fig. 11 ) use only peaks called by MACS2.
ChRO-seq and leChRO-seq data were mapped to hg19 as described above. A dREG score threshold was set at 0.7 to generate dREG peak regions. These dREG regions were used as input for dREG-HD. dREG-HD runs were under the 'stringent' condition, except for analysis of subtype-biased TREs, for which we used dREG-HD sites called under the 'relaxed' condition.
Mutual information analysis. We used mutual information to examine the similarity between TREs observed in any pair of DHS or dREG-HD datasets. DHSs or dREG-HD peaks of sample involved in the comparison were merged in order to construct a sample space in which two or more samples would be compared. Each dataset was then summarized as a random variable, represented by a zero-one vector in which each element represents a TREs in the sample space, and takes a value of 1 if it intersects with that peak, and a value of 0 otherwise. We calculated the mutual information (I) between two random variables, X and Y, using the formula: where X and Y∈ {0,1}, and represent the activation of TREs in two tissue types. Comparison between tumor and reference brain tissues and cell lines. We selected brain-related samples from uniformly processed DHSs and categorized the
Motif enrichment analysis of tumor-associated TREs and subtype-biased TREs.
Defining subtype-biased TREs. To search for TREs that differentially activated or repressed transcription in each subtype, we rely on measuring the change of the nascent RNA in the TRE regions. We merged dREG-HD sites called using the relaxed setting across 23 samples. We summed up the read counts of leChRO-seq and ChRO-seq of each merged dREG-HD site extended by 250 bp from the center. TREs in patients of the subtype of interest (Supplementary Table 5 ) were compared against those of the remaining three subtypes. Differential expression analysis was conducted using DESeq2 36 , and subtype-biased TREs are defined as those differentially transcribed with a FDR of less than 0.01.
Defining genomic regions for motif enrichment comparison. We compared motif enrichment in the positive set (the sequence set in which the motifs are found) with a GC-content-matched background control set. In the taTRE motif enrichment, we used the group indicated in Supplementary Fig. 15 as the positive set, and dREG-HD sites that intersect with active DHSs in the normal brain as the background. For subtype-biased TRE motif enrichment analyses we used upregulated or downregulated subtype-biased TREs as the positive set and TREs that did not show significant differential transcription (FDR, DESeq2, P > 0.1) as the background set. For the positive and background sets, we selected the center of peaks and then extended by 150 bp from the center. We subsampled background peaks to construct > 2,500 GC-content-matched TREs before scanning for motif enrichment.
Motif enrichment analysis. We used the R package rtfbsdb (v.0.4.0) to search for motifs that show enrichment in each primary GBM 47 . We focused on 1,882 human transcription factor binding motifs from the CisBP database 68 . When scanning genomic regions of interest, we used transcription factor binding sites with a log e -odds score of ≥ 7 in positive and background sets, with scores obtained by comparing each representative motif model to a second-order Markov background model. Motif enrichment was tested using Fisher's exact test. To account for potential bias resulting from the difference in GC content between positive and background sets, we ran a statistical test on 50 independently subsampled GCmatched dREG-HD regions, and summarized the P values and the fold enrichment across background sets using the median across samples. We refined motifs discovered using several heuristics, as follows: the motif was enriched (with a fold enrichment of > 1); the enrichment was robust to changes in the GC-matched background set (median P < 2.66 × 10 -5 = [0.05 / 1,882]); the positive sets have at least 10 sites with log e -odds scores of ≥ 7; the transcription factor was transcribed (for subtype-biased TREs). In the subtype-biased TRE analysis for upregulated TREs we required at least two ChRO-seq or leChRO-seq reads in the gene body in all samples of either the subtype of interest or the other three subtypes.
Summarizing motif enrichment statistics across patients. Motifs in the taTRE analysis that were enriched in at least one primary GBM (in the comparison between all taTRE against all normal brain TREs) were chosen for downstream analysis. The enrichment statistics of each transcription factor binding motif in all three regulatory modules or taTREs were summarized by median over the patients that show significant enrichment for the motif. Lastly, for each transcription factor with multiple motif IDs, we reported the one with the most significant enrichment in all taTREs over TREs found in the normal brain samples. In the subtype-biased TRE analysis, we used all motifs meeting the enrichment criteria and heuristics described above.
Motif clustering by genomic position. As we are not able to rigorously distinguish between paralogous transcription factors that share similar DNA binding specificities, we developed a method of clustering motifs based on their occurrences in the genome. We first scanned motifs enriched over genomic regions defined by the positive set. In clustering motifs enriched in taTREs, we used the taTREs merged over 20 primary GBMs as the positive set; for motifs enriched in subtype-biased TREs, we used the corresponding subtype-biased TRE in which the motifs were enriched as the positive set. We defined the presence of transcription factor binding sites for loci (stand-specific) as a log e -odds score of ≥ 7 in positive and background sets, and all other log e -odds scores as an absence, with scores obtained as described in the section on motif enrichment analysis of taTREs. The Spearman's rank order correlation coefficients were computed for each pair of transcription factors, based on their presence or absence pattern across transcription factor binding sites of all motifs of interest. Heatmaps were generated using agglomerative hierarchical clustering using ward.D2 in R.
Validation of regulation between transcription factors and target genes.
Association of transcription factors with target genes. We associated transcription factors with target genes by first identifying target TREs, and then searching for target genes based on the location of these TREs. To identify target TREs, we scanned 'relaxed dREG-HD all GBM' regions, extended by 150 bp from the TRE center. We identified occurences of each subtype-biased transcription factor binding motif in subtype-biased TREs that had a log e -odds score ≥ 7 compared with a second-order Markov model. The Markov model was fit using on DNA sequence in the TRE as the background. The subset of TREs with potential binding sites for each transcription factor are referred to as query TREs. We used stringent heuristics to link the query TREs to target genes to minimize false positive targets. TREs were linked to putative target genes if the annotated transcription start site of the genes was both of the first two closest to the query TRE and within 50 kb, and if the gene was differentially transcribed (P < 0.05, FDR-corrected Wald test, DESeq2) in the same direction as the query TRE.
Defining the background set of non-target genes. We defined background non-target genes of each transcription factor as those distal from (> 0.5 Mb) the query TRE, but which showed similar changes in transcription as target genes to control for subtype. We required non-target genes to have a transcription start site > 0.5 Mb from the closest query TRE. To match changes in transcription between target and non-target genes, we subsampled (without replacement) one-half of the genes away from query TREs and differentially transcribed (P < 0.05) in the same direction as target genes, such that the distribution of log 2 of fold change in transcription was insignificant (two-sided Wilcoxon rank-sum test, P > 0.2).
Validation of association between transcription factors and target genes.
To validate the approach that we used to associate transcription factors with target genes, we compared the co-expression of target genes to that of background non-target genes. Specifically, we used the reads per kilobase per million mapped reads (RPKM) normalized TCGA RNA-seq data from 174 patients with GBM, and used the Spearman's rank correlation to measure the degree of co-expression. To avoid the potential co-expression that might be artificially enriched in target genes owing to a higher chance of being located in adjacent positions of the genome, we masked the correlation coefficients between adjacent genes. We computed the significance of higher co-expression in target genes using the one-sided Wilcoxon rank-sum test.
Quantifying the association between the transcription level of transcription factors and their target genes. We used the RPKM-normalized TCGA RNA-seq data from 174 patients with GBM. We used Spearman's rank correlation to measure the relationship between the transcription level of transcription factors and the putative target genes. We compared the difference between the distribution of correlation coefficients for target and non-target genes using a two-sided Wilcoxon rank-sum test.
Identification of transcription factors driving survival-associated programs.
For each subtype-biased transcription factor, we identified the target genes as described above, and compared the hazard ratio of the target genes with that of non-target genes. We defined two background sets based on non-target genes: the closest genes whose transcription start site was within 50 kb of the query TRE, but whose transcription was unchanged across the samples representing that subtype (P > 0.2, Fig. 7a, x axis) ; and genes differentially transcribed (P < 0.05) in the same direction as target genes, whose transcription start sites were 0.5 Mb away from the closest query TRE (Fig. 7a, y axis) . We downloaded a table of mRNA expression values obtained using a microarray for 11,861 genes, and survival time in days for 196 patients with GBM from TCGA 32 . We computed the hazard ratio of each gene by fitting a Cox proportional hazards regression model for the survival time of patients with the highest 25% expression level over those with the lowest 25%. We used the Wilcoxon rank-sum test to compare the distribution of hazard ratios of target genes and background genes, and derived a two-tailed P value for each background set.
The hazard ratio for individual transcription factors in Fig. 7a and Supplementary Fig. 27a -c and target genes of survival-related transcription factors in Fig. 7e and Supplementary Figs . 27d,f and 30, were determined using the same regression model. The difference was that instead of using the upper and lower quartiles as the cutoff, we reported the hazard ratio at the threshold between the 0.1 quantile and 0.9 quantile that gave the largest difference between survival times. We tested this difference using a two-sided chi-squared test. This ensured that we reported the largest possible difference in survival time for each individual gene.
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